Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory randomized phase II study of trastuzumab deruxtecan versus physician’s choice endocrine therapy in low-HER2 hormone receptor-positive advanced breast cancer
KCT0009106Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trastuzumab deruxtecan in breast cancer (2 arms), sponsored by AstraZeneca. Started Apr 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0009106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009106.